OTCMKTS:SKVI

Skinvisible Competitors

$0.15
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.15
Now: $0.15
$0.15
50-Day Range
$0.09
MA: $0.13
$0.20
52-Week Range
$0.02
Now: $0.15
$0.27
Volume500 shs
Average Volume4,633 shs
Market Capitalization$670,800.00
P/E RatioN/A
Dividend YieldN/A
Beta-0.44

Competitors

Skinvisible (OTCMKTS:SKVI) Vs. NSPX, BTHE, VVUSQ, IMUCD, CAPS, and WWHC

Should you be buying SKVI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Skinvisible, including Inspyr Therapeutics (NSPX), Boston Therapeutics (BTHE), VIVUS (VVUSQ), ImmunoCellular Therapeutics (IMUCD), Capstone Therapeutics (CAPS), and W World (WWHC).

Skinvisible (OTCMKTS:SKVI) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Skinvisible and Inspyr Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Skinvisible-1,027.05%N/A-834.18%
Inspyr TherapeuticsN/AN/A-298.11%

Valuation and Earnings

This table compares Skinvisible and Inspyr Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Skinvisible$40,000.0016.77$-1,700,000.00N/AN/A
Inspyr TherapeuticsN/AN/A$-930,000.00N/AN/A

Inspyr Therapeutics has lower revenue, but higher earnings than Skinvisible.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Skinvisible and Inspyr Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Skinvisible0000N/A
Inspyr Therapeutics0000N/A

Volatility & Risk

Skinvisible has a beta of -0.44, meaning that its stock price is 144% less volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of -16.55, meaning that its stock price is 1,755% less volatile than the S&P 500.

Summary

Inspyr Therapeutics beats Skinvisible on 3 of the 5 factors compared between the two stocks.

Skinvisible (OTCMKTS:SKVI) and Boston Therapeutics (OTCMKTS:BTHE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Skinvisible and Boston Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Skinvisible0000N/A
Boston Therapeutics0000N/A

Profitability

This table compares Skinvisible and Boston Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Skinvisible-1,027.05%N/A-834.18%
Boston Therapeutics-24,627.27%N/A-3,480.61%

Valuation and Earnings

This table compares Skinvisible and Boston Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Skinvisible$40,000.0016.77$-1,700,000.00N/AN/A
Boston Therapeutics$20,000.00111.13$-3,690,000.00N/AN/A

Skinvisible has higher revenue and earnings than Boston Therapeutics.

Volatility & Risk

Skinvisible has a beta of -0.44, meaning that its stock price is 144% less volatile than the S&P 500. Comparatively, Boston Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500.

Summary

Skinvisible beats Boston Therapeutics on 4 of the 6 factors compared between the two stocks.

VIVUS (OTCMKTS:VVUSQ) and Skinvisible (OTCMKTS:SKVI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares VIVUS and Skinvisible's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VIVUS-39.28%N/A-12.18%
Skinvisible-1,027.05%N/A-834.18%

Institutional and Insider Ownership

7.3% of VIVUS shares are held by institutional investors. 12.0% of VIVUS shares are held by insiders. Comparatively, 53.0% of Skinvisible shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares VIVUS and Skinvisible's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVUS$69.76 million0.03$-31,500,000.00($2.96)-0.04
Skinvisible$40,000.0016.77$-1,700,000.00N/AN/A

Skinvisible has lower revenue, but higher earnings than VIVUS.

Analyst Ratings

This is a summary of recent ratings and recommmendations for VIVUS and Skinvisible, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VIVUS0000N/A
Skinvisible0000N/A

Risk and Volatility

VIVUS has a beta of -3.25, meaning that its stock price is 425% less volatile than the S&P 500. Comparatively, Skinvisible has a beta of -0.44, meaning that its stock price is 144% less volatile than the S&P 500.

Skinvisible (OTCMKTS:SKVI) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Skinvisible and ImmunoCellular Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Skinvisible0000N/A
ImmunoCellular Therapeutics0000N/A

Profitability

This table compares Skinvisible and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Skinvisible-1,027.05%N/A-834.18%
ImmunoCellular TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Skinvisible and ImmunoCellular Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Skinvisible$40,000.0016.77$-1,700,000.00N/AN/A
ImmunoCellular TherapeuticsN/AN/A$-14,310,000.00N/AN/A

Skinvisible has higher revenue and earnings than ImmunoCellular Therapeutics.

Volatility & Risk

Skinvisible has a beta of -0.44, suggesting that its share price is 144% less volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Summary

ImmunoCellular Therapeutics beats Skinvisible on 3 of the 5 factors compared between the two stocks.

Capstone Therapeutics (OTCMKTS:CAPS) and Skinvisible (OTCMKTS:SKVI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Capstone Therapeutics has a beta of 176.15, suggesting that its share price is 17,515% more volatile than the S&P 500. Comparatively, Skinvisible has a beta of -0.44, suggesting that its share price is 144% less volatile than the S&P 500.

Valuation & Earnings

This table compares Capstone Therapeutics and Skinvisible's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$2 million0.97$-380,000.00N/AN/A
Skinvisible$40,000.0016.77$-1,700,000.00N/AN/A

Capstone Therapeutics has higher revenue and earnings than Skinvisible.

Institutional and Insider Ownership

2.6% of Capstone Therapeutics shares are held by institutional investors. 42.8% of Capstone Therapeutics shares are held by insiders. Comparatively, 53.0% of Skinvisible shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Capstone Therapeutics and Skinvisible's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Capstone TherapeuticsN/AN/AN/A
Skinvisible-1,027.05%N/A-834.18%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Capstone Therapeutics and Skinvisible, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Capstone Therapeutics0000N/A
Skinvisible0000N/A

Summary

Capstone Therapeutics beats Skinvisible on 6 of the 8 factors compared between the two stocks.

W World (OTCMKTS:WWHC) and Skinvisible (OTCMKTS:SKVI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Volatility & Risk

W World has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Skinvisible has a beta of -0.44, suggesting that its stock price is 144% less volatile than the S&P 500.

Earnings and Valuation

This table compares W World and Skinvisible's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
W WorldN/AN/AN/AN/AN/A
Skinvisible$40,000.0016.77$-1,700,000.00N/AN/A

W World has higher earnings, but lower revenue than Skinvisible.

Profitability

This table compares W World and Skinvisible's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
W WorldN/AN/AN/A
Skinvisible-1,027.05%N/A-834.18%

Institutional & Insider Ownership

0.1% of W World shares are held by institutional investors. 61.1% of W World shares are held by insiders. Comparatively, 53.0% of Skinvisible shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for W World and Skinvisible, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
W World0000N/A
Skinvisible0000N/A

Summary

W World beats Skinvisible on 5 of the 6 factors compared between the two stocks.


Skinvisible Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NSPX
Inspyr Therapeutics
0.5$0.02flat$2.34 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$2.22 million$20,000.00-1.00
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48flat$2.01 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01flat$1.95 million$2 million0.00High Trading Volume
Gap Down
WWHC
W World
0.8$6.09flat$1.80 millionN/A0.00Increase in Short Interest
News Coverage
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03flat$1.70 million$530,000.000.00Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.48flat$1.69 millionN/A0.00
Cardax logo
CDXI
Cardax
0.0$2.10flat$1.67 million$710,000.000.00
MLNTQ
Melinta Therapeutics
0.2$0.11flat$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.31 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57Decrease in Short Interest
News Coverage
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$1.11 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.01flat$1.05 millionN/A0.00
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.22flat$1.03 millionN/A0.00Decrease in Short Interest
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03flat$963,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$928,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08flat$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.02flat$772,000.00N/A0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03flat$749,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00flat$678,000.00N/A0.00Increase in Short Interest
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15flat$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17flat$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07flat$378,000.00N/A0.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02flat$374,000.00N/A0.00Increase in Short Interest
Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00News Coverage
Gap Up
PZRXQ
PhaseRx
0.2$0.03flat$298,000.00N/A0.00Decrease in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60flat$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09flat$124,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02flat$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02flat$9,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.03flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.09flat$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50flat$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49flat$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$35.36flat$0.00N/A0.00Decrease in Short Interest
News Coverage
Gap Down
HRBR
Harbor Diversified
0.0$1.16flat$0.00$263.61 million0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.